Correction: Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: A randomized, open-label, review board–blinded 15-month study (Journal of Clinical Psychiatry (2015) 76:5 (554–561) DOI: 10.4088/JCP.14m09584);Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: A randomized, open-label, review board-blinded 15-month study

Journal of Clinical Psychiatry

Volumn 76, Issue 5, 2015, Pages 554-561

  Alphs, Larry ^a   Benson, Carmela ^a   Cheshire Kinney, Kimberly ^a   Lindenmayer, Jean Pierre ^b   Mao, Lian ^a   Rodriguez, Stephen C ^a   Starr, H Lynn ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; HALOPERIDOL; HYPNOTIC AGENT; MOOD STABILIZER; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PALMITIC ACID DERIVATIVE;

ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; BACKACHE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DSM-IV; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INCREASED APPETITE; INJECTION SITE PAIN; INSOMNIA; LIBIDO DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL HEALTH SERVICE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; TOOTH PAIN; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL; COMPARATIVE STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; OFFENDER; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CRIMINALS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84932158351     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.19LCX12829     Document Type: Erratum

References (30)

1. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85-94.
2. National Institute of Mental Health. Schizophrenia. http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. Accessed February 5, 2015.
3. Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63-76.
4. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279-293.
5. Hoge SK. Providing transition and outpatient services to the mentally ill released from correctional institutions. In: Greifinger RB, ed. Public Health Behind Bars: From Prisons to Communities. Dobbs Ferry, NY: Springer; 2007:461-477.
6. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia. BMC Psychiatry. 2010;10(1):11.
7. Folsom D, Jeste DV. Schizophrenia in homeless persons: a systematic review of the literature. Acta Psychiatr Scand. 2002;105(6):404-413.
8. Robinson D, Woerner MG, Pollack S, et al. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol. 1996;16(2):170-176.
9. Hofer A, Hummer M, Huber R, et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20(6):699-702.
10. Fleischhacker WW, Hummer M. Do phase III trials have clinical value? J Clin Psychopharmacol. 1999;19(5):391-392.
11. Fleischhacker WW, Kemmler G. The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology. 2007;32(11):2435-2436.
12. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15-31.
13. Wilk J, Marcus SC, West J, et al. Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis. 2006;194(6):454-457.
14. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res. 2002;54(3):253-264.
15. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247-256.
16. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117.
17. Bai YM, Chen TT, Wu B, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry. 2006;39(4):135-141.
18. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31.
19. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.
20. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-965.
21. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(suppl):S37-S41.
22. Fleischhacker WW, Goodwin GM. Effectiveness as an outcome measure for treatment trials in psychiatry. World Psychiatry. 2009;8(1):23-27.
23. Alphs L, Mao L, Rodriguez SC, et al. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. J Clin Psychiatry. 2014;75(12):1388-1393.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
25. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
26. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50(10):792-801.
27. Kuehn BM. Criminal justice becomes front line for mental health care. JAMA. 2014;311(19):1953-1954.
28. Kunz M, Yates KF, Czobor P, et al. Course of patients with histories of aggression and crime after discharge from a cognitive-behavioral program. Psychiatr Serv. 2004;55(6):654-659.
29. Harris V, Koepsell TD. Criminal recidivism in mentally ill offenders: a pilot study. Bull Am Acad Psychiatry Law. 1996;24(2):177-186.
30. Feder L. A comparison of the community adjustment of the mentally ill offenders with those from the general prison population. Law Hum Behav. 1991;15(5):477-493.